Understanding therapeutic targets in thrombotic thrombocytopenic purpura

被引：15
作者：
Joly, Berangere S. [1 ,2 ]
Vanhoorelbeke, Karen [3 ]
Veyradier, Agnes [1 ,2 ]
机构：
[1] Univ Paris Diderot, Grp Hosp St Louis Lariboisiere, Assistance Publ Hop Paris, Serv Hematol Biol, 2 Rue Ambroise Pare, F-75010 Paris, France
[2] Univ Paris Diderot, Grp Hosp St Louis Lariboisiere, Assistance Publ Hop Paris, Inst Univ Hematol EA3518, 2 Rue Ambroise Pare, F-75010 Paris, France
[3] Katholieke Univ Leuven, IRF Life Sci, Lab Thrombosis Res, Campus Kulak Kortrijk, Kortrijk, Belgium
来源：
INTENSIVE CARE MEDICINE | 2017年 / 43卷 / 09期
基金：
欧盟地平线“2020”;
关键词：
VON-WILLEBRAND-FACTOR; FACTOR-CLEAVING PROTEASE; ADAMTS13; PATHOPHYSIOLOGY; ANTIBODIES; PLASMA; TTP;
D O I：
10.1007/s00134-016-4662-3
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：1398 / 1400
页数：3
相关论文
共 19 条
  • [1] Recombinant ADAMTS 13 Attenuates Brain Injury After Intracerebral Hemorrhage
    Cai, Ping
    Luo, Haiyu
    Xu, Haochen
    Zhu, Ximin
    Xu, Wenfang
    Dai, Yiqin
    Xiao, Jin
    Cao, Yongliang
    Zhao, Yuwu
    Zhao, Bing-Qiao
    Fan, Wenying
    [J]. STROKE, 2015, 46 (09) : 2647 - 2653
  • [2] N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice
    Chen, Junmei
    Reheman, Adili
    Gushiken, Francisca C.
    Nolasco, Leticia
    Fu, Xiaoyun
    Moake, Joel L.
    Ni, Heyu
    Lopez, Jose A.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (02) : 593 - 603
  • [3] Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
    Furlan, M
    Robles, R
    Galbusera, M
    Remuzzi, G
    Kyrle, PA
    Brenner, B
    Krause, M
    Scharrer, I
    Aumann, V
    Mittler, U
    Solenthaler, M
    Lämmle, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) : 1578 - 1584
  • [4] Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura
    George, James N.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S88 - S91
  • [5] Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura
    Jian, Cui
    Xiao, Juan
    Gong, Lingjie
    Skipwith, Christopher G.
    Jin, Sheng-Yu
    Kwaan, Hau C.
    Zheng, X. Long
    [J]. BLOOD, 2012, 119 (16) : 3836 - 3843
  • [6] Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura
    Jilina-Stohlawetz, Petra
    Gorczyca, Monika E.
    Jilma, Bernd
    Siller-Matula, Jolanta
    Gilbert, James C.
    Knoebl, Paul
    [J]. THROMBOSIS AND HAEMOSTASIS, 2011, 105 (03) : 545 - 552
  • [7] Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy
    Joly, Berangere S.
    Stepanian, Alain
    Leblanc, Thierry
    Hajage, David
    Chambost, Herve
    Harambat, Jerome
    Fouyssac, Fanny
    Guigonis, Vincent
    Leverger, Guy
    Ulinski, Tim
    Kwon, Theresa
    Loirat, Chantal
    Coppo, Paul
    Veyradier, Agnes
    [J]. LANCET HAEMATOLOGY, 2016, 3 (11): : E537 - E546
  • [8] Understanding organ dysfunction in thrombotic thrombocytopenic purpura
    Mannucci, Pier Mannuccio
    [J]. INTENSIVE CARE MEDICINE, 2015, 41 (04) : 715 - 718
  • [9] Mariotte E, 2016, LANCET HAEMATOL, V3, pE237, DOI [10.1016/S2352-3026(16)30018-7, 10.1016/s2352-3026(16)30018-7]
  • [10] Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
    Peyvandi, Flora
    Scully, Marie
    Hovinga, Johanna A. Kremer
    Cataland, Spero
    Knoebl, Paul
    Wu, Haifeng
    Artoni, Andrea
    Westwood, John-Paul
    Taleghani, Magnus Mansouri
    Jilma, Bernd
    Callewaert, Filip
    Ulrichts, Hans
    Duby, Christian
    Tersago, Dominique
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (06) : 511 - 522
12